论文部分内容阅读
TO THE EDITORRituximab is a chimeric monoclonal antibody againstCD20 antigen expressed on most B cells and is used forthe treatment of malignant lymphomas expressing theCD20 antigen.It temporarily eliminates normal B-lym-phocytes without a substantial decrease in serum immuno-globulin levels.Recently,several serious viral infectionshave been reported in association with rituximab use.Cy-tomegalovirus(CMV)is one of the agents that may be acause of morbidity and mortality in immunocompromisedindividuals.In the face of exogenous or endogenouscauses of immunosuppression,cytomegalovirus can result
TO THE EDITORRituximab is a chimeric monoclonal antibody againstCD20 antigen expressed on most B cells and is used forthe treatment of malignant lymphomas expressing theCD20 antigen .It temporarily eliminates normal B-lym-phocytes without a substantial decrease in serum immuno-globulin levels. serious viral infections have been reported in association with rituximab use. Cytomegalovirus (CMV) is one of the agents that may be acause of morbidity and mortality in immunocompromisedindividuals. In the face of exogenous or endogenous cancers of immunosuppression, cytomegalovirus can result